Cadrenal TherapeuticsCVKD
13F holders, Q1 2026 (March 31)3holders +1
1new positions
0sold out
$5.08avg. 13F price*
At the end of Q1 2026, 3 institutions reported holding Cadrenal Therapeutics Inc. (CVKD) in their 13F filings, up 1 from Q4 2025. 1 opened new positions and 0 sold out. The largest holders were Harbour Investments, Inc. ($512), Farther Finance Advisors, LLC ($123) and Caldwell Sutter Capital, Inc. ($26).
- Company
- Cadrenal Therapeutics Inc.
- CUSIP
- 127636108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $512 |
| Exits | 0 | $0 |
All 13F filers, Q4 2025 → Q1 2026: 100 shares bought, net +100 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Harbour Investments, Inc. | 0.00% | New | 100 | $512 |
| Farther Finance Advisors, LLC | 0.00% | No change | 25 | $123 |
| Caldwell Sutter Capital, Inc. | 0.00% | No change | 5 | $26 |
"% of holder's portfolio" is CVKD's weight in each manager's 13F, not the share of Cadrenal Therapeutics Inc. the manager owns.